Noticias - Desert King

Chile Approves New Shingles Vaccine Featuring Desert King Saponins

This milestone marks the arrival of a more effective and safer vaccine that incorporates Chilean quillay extract as an immunological adjuvant. Chile’s Public Health...

Chile aprueba nueva vacuna contra el herpes zóster que incluye saponinas de Desert King

Este hito marca la llegada de una vacuna más eficaz y segura, que incorpora extracto de quillay chileno como adyuvante inmunológico. El Instituto de Salud Pública (ISP)...

Pallerla, S., et al. Scale-up and cGMP manufacturing of next-generation vaccine adjuvant Saponin/MPLA NanoParticles (SMNP). J Pharm Sci, 2025 Jul 19, 114(9):103913.

Pallerla, S., et al. Scale-up and cGMP manufacturing of next-generation vaccine adjuvant Saponin/MPLA NanoParticles (SMNP). J Pharm Sci, 2025 Jul 19, 114(9):103913. PMID:...

Zhou, S.H., et al. Engineered hybrid membrane vesicles combined with autologous and synthetic antigens as therapeutic vaccines to efficiently suppress tumor recurrence. J Control Release, 2025 Jun 24, 385:113979.

Zhou, S.H., et al. Engineered hybrid membrane vesicles combined with autologous and synthetic antigens as therapeutic vaccines to efficiently suppress tumor recurrence. J...

Patel, N., et al. Single-dose avian influenza A(H5N1) Clade 2.3.4.4b hemagglutinin-Matrix-M® nanoparticle vaccine induces neutralizing responses in nonhuman primates. Nat Commun, 2025 Jul 18, 16(1):6625.

Patel, N., et al. Single-dose avian influenza A(H5N1) Clade 2.3.4.4b hemagglutinin-Matrix-M® nanoparticle vaccine induces neutralizing responses in nonhuman primates. Nat...

Scaria, P.V., et al. SARS-CoV-2 Receptor Binding Domain (RBD) Protein-Protein Conjugate Induces Similar or Better Antibody Responses as Spike mRNA in Rhesus Macaques. Vaccines (Basel), 2025 Jun 17, 13(6):648.

Scaria, P.V., et al. SARS-CoV-2 Receptor Binding Domain (RBD) Protein-Protein Conjugate Induces Similar or Better Antibody Responses as Spike mRNA in Rhesus Macaques. Vac...

Dagnew, A.F., et al. Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E4 in people living with HIV in South Africa: an observer-blinded, randomised, controlled, phase 2 trial. Lancet HIV, 2025 Aug, 12(8):e546-e555.

Dagnew, A.F., et al. Safety and immunogenicity of investigational tuberculosis vaccine M72/AS01E4 in people living with HIV in South Africa: an observer-blinded, randomis...

Caniels, T.G., et al. Precise targeting of HIV broadly neutralizing antibody precursors in humans. Science, 2025 Jul 31, 389(6759):eadv5572.

Caniels, T.G., et al. Precise targeting of HIV broadly neutralizing antibody precursors in humans. Science, 2025 Jul 31, 389(6759):eadv5572. PMID: 40373114 This research ...